IMS works with a variety of media outlets and trade associations to share expertise on issues impacting the pharmaceutical industry. This section provides abstracts and PDFs of current published articles, as well as extracts from recent industry presentations.

Page: <<  1  2  3  4  5  6  7  8  9  10

Doctors & DTC
Since 1997, the pharmaceutical industry's annual investment in direct-to-consumer (DTC) advertising in the U.S. has grown from $965 million to $2.6 billion in 2001.
Sep 5, 2002

Alzheimer’s Disease: Major Market Here To Stay
The National Institute on Aging (NIA) estimates that the annual cost of caring for a patient with a mild form of Alzheimer’s Disease (AD) is more than $18,000, climbing to $36,000 annually for those who suffer from a severe form of the disease.
Aug 1, 2002

Business Watch: 2001 In Review
Sales in the year ending December 31, 2001 increased by 16.9% – a high performing year for the US pharmaceutical industry. Total sales in the industry reached $173 billion, while growth in dispensed prescriptions remained at 6%.
Jun 21, 2002

DTC’s Role in the Statin Bonanza
Cholesterol-reducing ‘statins’ have been among the fastest growing ethical pharmaceuticals during the past several years.
Feb 25, 2002

Flexing Their Budgets: Big Pharma Spend Trends
Pharmaceutical promotional spends in direct-to-consumer and the professional sector are still on the rise according to 2000 data. Yet, some growth curves seem to be slowing as a result of the industry's reaction to the economic downturn in the U.S.
Oct 5, 2001

Power to the People – Reaching the Smart Market of Empowered Consumers
Pharmaceutical marketers are addressing the phenomenon of the empowered consumer, having spent a record $2.5 billion in 2000 to reach them with their messages.
Sep 17, 2001

Business Watch: 2000 In Review
The U.S. pharmaceutical industry delivered strong performance in 2000, even if it did not shatter existing growth records.
Jul 18, 2001

Pharma‘s Future – There’s Still Gold in Them Thar Pills
Pharmaceutical stocks have shone for decades as growth stalwarts relatively unaffected by economic turbulence – they‘ve been beacons of dependability. Today the argument for loading up on such stocks seem stronger than ever.
Jul 18, 2001

Page: <<  1  2  3  4  5  6  7  8  9  10

Home | Contact | Search | Site Map | FAQ | Privacy | Websites
Copyright © 2007 IMS Health Incorporated. All rights reserved.